Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03472586
Other study ID # 18P.042
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 2, 2018
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.


Description:

PRIMARY OBJECTIVES: I. Determine the clinical benefit of treatment with immunoembolization (IEMBO) in combination with ipilimumab and nivolumab. SECONDARY OBJECTIVES: I. Determine all treatment and immune related toxicities. II. Determine progression free survival. III. Determine overall survival.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 14
Est. completion date December 31, 2024
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is >= 10 mm in longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI) - The total volume of the tumors must be less than 50% of the liver volume - Willingness and ability to give informed consent - Agreement to access archival tissue or agreement for tumor biopsy prior to treatment - Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 - Serum creatinine =< 2.0 mg/dl - Granulocyte count >= 1000/mm^3 - Platelet count >= 100,000/mm^3 - Bilirubin =< 2.0 mg/ml - Albumin >= 3.0 g/dl - Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN) - Alkaline phosphatase less than 1.5 times ULN (grade 1) - Women must not be pregnant or breast-feeding - Women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 23 weeks after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 31 weeks after the last dose of nivolumab and/or ipilimumab Exclusion Criteria: - Failure to meet any of the criteria set forth in the inclusion criteria section - Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody - Previous liver-directed treatments including chemoembolization, radiosphere, hepatic arterial perfusion, or drug-eluting beads; liver resection and focal ablation are permitted - Presence of symptomatic liver failure including ascites and hepatic encephalopathy - Presence of untreated brain metastases; if patients have had previous treatment for the brain metastasis, an MRI or CT scan of the brain must confirm the stabilization of the brain metastasis for more than 2 months - Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry - Presence of any other medical complication that implies survival of less than six months - Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding - Significant allergic reaction to contrast dye or granulocyte-macrophage colony-stimulating (GM-CSF) - Immunosuppressive treatments within 4 weeks prior to embolization, unless prednisone =< 5 mg or equivalent - Pregnancy or breast-feeding women - Patients with active hepatitis with serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) equal or greater than 5 times normal - Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy - Positive for known human immunodeficiency virus (HIV) Infection - Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis - Active infection - Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis, but not including hypothyroidism or psoriasis if condition has been stable for 2 months or greater

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Ipilimumab
Given IV
Nivolumab
Given IV
Drug:
Embolization Therapy
Undergo immunoembolization

Locations

Country Name City State
United States Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Cancer Center at Thomas Jefferson University Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) Defined as complete response + partial response + stable disease. Rated by Response Evaluation Criteria in Solid Tumors version 1.1. The estimate of the hepatic metastasis stabilization rate will be presented with corresponding 95% confidence intervals. The method of Atkinson and Brown will be used to adjust for the two-stage design. At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days.
Secondary Incidence of Adverse Events Graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Toxicity rates will be estimated with corresponding 95% confidence intervals. Up to 1 year
Secondary Progression Free Survival (PFS) Will be estimated using the Kaplan-Meier method. From the start of the treatment to confirmation of progression of disease, assessed up to 1 year
Secondary Overall Survival Will be estimated using the Kaplan-Meier method. From the start of the treatment to confirmation of progression of disease, assessed up to 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03068624 - Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 1
Recruiting NCT04728633 - Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Phase 2
Recruiting NCT05987332 - IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Phase 2/Phase 3
Completed NCT01551459 - A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT01585194 - Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 2
Withdrawn NCT01328106 - Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma Phase 2
Recruiting NCT05075993 - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04552223 - Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Phase 2
Recruiting NCT05607095 - Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Phase 1
Active, not recruiting NCT01587352 - Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Phase 2
Active, not recruiting NCT03025256 - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Phase 1
Terminated NCT04879017 - FHD-286 in Subjects With Metastatic Uveal Melanoma Phase 1
Terminated NCT01814046 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Phase 2
Recruiting NCT03947385 - Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Phase 1/Phase 2
Active, not recruiting NCT03865212 - Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Phase 1
Active, not recruiting NCT05022901 - An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Phase 3
Recruiting NCT05282901 - Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Phase 2
Recruiting NCT05415072 - A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Phase 1/Phase 2
Active, not recruiting NCT04720417 - Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma Phase 2